August 10, 2020 10:31 AM EDT
R&D

In­novent and Eli Lil­ly chal­lenge Mer­ck­'s mega-block­buster Keytru­da in non-small cell lung can­cer field

Nicole DeFeudis

Editor

Chi­na-based In­novent Bi­o­log­ics and its multi­na­tion­al al­ly Eli Lil­ly shared Phase III ev­i­dence that their PD-1 in­hibitor com­bo can de­lay the pro­gres­sion of non­squa­mous non …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

Chica­go’s biotech scene is grow­ing up. What’s fu­el­ing it?

UCB, No­var­tis say a Phase 2a Parkin­son's study failed

Pfiz­er’s mes­sage to in­vestors: The ship is steady­ing in 2025 (even if Wash­ing­ton is tur­bu­lent)

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Jazz Phar­ma­ceu­ti­cals CEO and co-founder Bruce Cozadd is re­tir­ing

A service from the Financial Times